1Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy [ J ]. Blood, 2000,96 (9) : 2943-2950.
2Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma[J]. N Engl J Med, 1999, 341 (21):1565-1571.
3Weber DM, Gavino M, Delasalle K, et al. Thalidomide alone or with dexamethasone for multiple myeloma[ J]. Blood, 1999, 94 [ Suppl 1 ] :604a.
4Durie BGM, Stepan DE. Efficacy of low dose thalidomide(T)in multiple myeloma [J]. Blood, 1999,94[Suppl 1] :316a.
5Juliusson G,Celsing F, Turesson I, et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma[J]. Br J Haematol, 2000, 109(1):89-96.
6Kneller A, Raanani P, Hardan I, et al. Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug[J]. Br J Haematol, 2000,108 (2) : 391-393.
7Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed and refractory myeloma[ J]. Blood, 1999,94[ Suppl 1] :316a.
8Shima Y,Treon SP, Yoshizaki K, et al. Clinical and biological activity of thalidomide(THAL) in multiple myeloma(MM) [ J]. Blood, 1999,94[ Suppl 1 ] : 125a.
9Neben K, Hawighorst H, Moehler TM, et al. Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic response(d-MRI) angiogenesis parameters [ J ]. Blood, 1999,94 [ Suppl1] : 124a.
10Sabir T, Raza S, Anderson L, et al. Thalidomide is effective in the treatment of recurrent refractory multiple myeloma(MM) [J]. Blood,1999,94[ Suppl 1 ] : 125a.
